Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN FRANCISCO: SAN FRANCISCO, Nov. 12, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. Initial clinical results were presented from the dose-escalation stage of a Phase 1/2 study of NKTR-255 in...

Click to view original post